{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:51:41Z","timestamp":1761749501145,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.path.2023.01.012","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:24:09Z","timestamp":1678289049000},"page":"411-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Julia T.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Kluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2023.01.012_bib1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Clinical Practice Guideline. www.NCCN.org. Version 2.2022. 2022."},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.path.2023.01.012_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.path.2023.01.012_bib4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.path.2023.01.012_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.path.2023.01.012_bib6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.leukres.2011.04.006","article-title":"Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL)","volume":"35","author":"Uhrmacher","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.path.2023.01.012_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cyto.b.21936","article-title":"Determination of CD43 and CD200 surface expression improves accuracy of B-cell lymphoma immunophenotyping","volume":"98","author":"Hoffmann","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.path.2023.01.012_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1309\/AJCPBV9ELXC0ECVL","article-title":"Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging","volume":"142","author":"Challagundla","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.path.2023.01.012_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cytob.21128","article-title":"CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry","volume":"86","author":"Sandes","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.path.2023.01.012_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3109\/10428194.2014.953147","article-title":"Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma from mantle cell lymphoma","volume":"56","author":"Wasik","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib11","article-title":"CD81 Expression in the Differential Diagnosis of Chronic Lymphocytic Leukemia","volume":"65","author":"Afacan-\u00d6zt\u00fcrk","year":"2019","journal-title":"Clin Lab"},{"issue":"1","key":"10.1016\/j.path.2023.01.012_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"10.1016\/j.path.2023.01.012_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.path.2023.01.012_bib14","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.path.2023.01.012_bib15","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pathol.2021.01.006","article-title":"The future of laboratory testing in chronic lymphocytic leukaemia","volume":"53","author":"Hotinski","year":"2021","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.path.2023.01.012_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2019.03.014","article-title":"Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis","volume":"19","author":"Molica","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.path.2023.01.012_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.path.2023.01.012_bib19","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2023.01.012_bib21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A\u00a0complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.path.2023.01.012_bib22","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428194.2021.1919658","article-title":"A\u00a010-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","volume":"62","author":"Bazinet","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.path.2023.01.012_bib23","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: a decade later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2017.296","article-title":"NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-\u03baB pathways","volume":"32","author":"Benedetti","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.path.2023.01.012_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1479-5876-8-23","article-title":"Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T\/B ratio versus percentage of positive cells","volume":"8","author":"Rossi","year":"2010","journal-title":"J\u00a0Transl Med"},{"issue":"2","key":"10.1016\/j.path.2023.01.012_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3324\/haematol.11622","article-title":"Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method","volume":"93","author":"Gachard","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.path.2023.01.012_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cyto.b.20622","article-title":"Combined normal donor and CLL: Single tube ZAP-70 analysis","volume":"82","author":"Degheidy","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.path.2023.01.012_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1751-553X.2010.01263.x","article-title":"MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal","volume":"33","author":"Marquez","year":"2011","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.path.2023.01.012_bib30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1046\/j.1365-2141.2001.03149.x","article-title":"Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia","volume":"115","author":"Jelinek","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.path.2023.01.012_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"D\u00fcrig","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.path.2023.01.012_bib32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.path.2023.01.012_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2023.01.012_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cyto.b.21384","article-title":"CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"94","author":"Gooden","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.path.2023.01.012_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-4939-9650-6_17","article-title":"Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia","volume":"2032","author":"Salem","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib37","first-page":"292","article-title":"Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas","volume":"147","author":"Menter","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.path.2023.01.012_bib38","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2011.103","article-title":"Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia\/small lymphocytic lymphoma in small B-cell lymphomas","volume":"24","author":"Tandon","year":"2011","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib39","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\"accelerated\" chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41379-019-0356-z","article-title":"Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis","volume":"33","author":"Liu","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2023.01.012_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.humpath.2018.07.030","article-title":"Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption","volume":"82","author":"Garces","year":"2018","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib42","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jmoldx.2020.06.004","article-title":"Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia","volume":"22","author":"Lee","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.path.2023.01.012_bib44","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2023.01.012_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.path.2023.01.012_bib46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.path.2023.01.012_bib47","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2014-09-600874","article-title":"Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations","volume":"125","author":"Baliakas","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib48","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","article-title":"Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies","volume":"105","author":"Delgado","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.path.2023.01.012_bib49","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.path.2023.01.012_bib50","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.path.2023.01.012_bib51","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2023.01.012_bib52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.path.2023.01.012_bib53","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Eugen","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.path.2023.01.012_bib54","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.path.2023.01.012_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136109","article-title":"Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed\/Refractory Chronic Lymphocytic Leukemia (R\/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)","volume":"136","author":"Kater","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.path.2023.01.012_bib56","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1080\/10428194.2017.1397664","article-title":"Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry","volume":"59","author":"Aw","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.path.2023.01.012_bib57","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.path.2023.01.012_bib58","series-title":"Chronic lymphocytic leukemia: methods and protocols","first-page":"27","article-title":"Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia","author":"Miller","year":"2019"},{"issue":"6","key":"10.1016\/j.path.2023.01.012_bib59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cyto.b.21875","article-title":"Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples","volume":"98","author":"Bento","year":"2020","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918123000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918123000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:43:30Z","timestamp":1761749010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918123000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1875918123000120"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2023.01.012","relation":{},"ISSN":["1875-9181"],"issn-type":[{"type":"print","value":"1875-9181"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2023.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}